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Background: Mean platelet volume has been associated with stroke in patients with atrial fibrillation. However, its
role as a predictor of left atrial stasis, assessed by transesophageal echocardiography, in patients with non-valvular
atrial fibrillation has not yet been clarified.
Methods: Single center cross-sectional study comprising 427 patients admitted to the emergency department due
to symptomatic atrial fibrillation and undergoing transesophageal echocardiogram evaluation for exclusion of left
atrial appendage thrombus before cardioversion. All patients had a complete blood count performed in the
12 hours prior to transesophageal echocardiogram. Markers of left atrial stasis were sought: left atrial appendage
thrombus, dense spontaneous echocardiographic contrast and low flow velocities in the left atrial appendage. The
presence of at least one of the former markers of left atrial stasis was designated left atrial abnormality. Binary
logistic multivariate analysis was used for obtaining models for the prediction of transesophageal echocardiogram
endpoints.
Results: Left atrial appendage thrombus was found in 12.2%, dense spontaneous echocardiographic contrast
in 29.7%, low flow velocities in 15.3% and left atrial abnormality in 34.2%. Mean platelet volume (exp β = 3.41
p = 0.048) alongside with previous stroke or transient ischemic attack (exp β = 5.35 p = 0.005) and troponin I
(exp β = 5.07 p = 0.041) were independent predictors of left atrial appendage thrombus. Mean platelet volume
was also incorporated in the predictive models of dense spontaneous echocardiographic contrast, low flow
velocities and left atrial abnormality, adding predictive value to clinical, echocardiographic and laboratory variables.
Conclusions: These findings suggest that mean platelet volume may be associated with the presence of markers
of left atrial stasis, reinforcing a likely cardioembolic mechanism for its association with stroke in patients with
non-valvular atrial fibrillation.
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Thromboembolism is one of the most feared complica-
tions of atrial fibrillation (AF) [1]. It may arise due to AF
in the course of time or it may be facilitated by proce-
dures like cardioversion or percutaneous AF ablation,
when a thrombus is present in the left atrium. Therefore,* Correspondence: rui_providencia@yahoo.com
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distribution, and reproduction in any mediumbefore undergoing risk procedures like catheter ablation
or cardioversion of AF a pre-procedural transesophageal
echocardiogram may be advisable in order to minimize
post-procedure thromboembolic complications [2,3].
The possibility of using biomarkers for thrombo-
embolic risk stratification of patients with atrial fibrilla-
tion is a field of growing interest. The role of mean
platelet volume (MPV) as a predictive marker of stroke
in patients with AF has been recently suggested by Ha
and colleagues [4]. In this investigation, MPV was shownntral Ltd. This is an Open Access article distributed under the terms of the
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ables present in the CHADS2 score.
Very recently, it was also shown in a case–control
study that stroke patients with AF displayed higher
MPV levels than patients with AF without stroke history
of stroke [5]. These authors established a cut-off level of
MPV > 9.4 fL for this association (OR 4.021 p < 0.001).
However, the precise mechanism underlying this rela-
tionship (cardiac embolism or peripheral thrombosis due
to increased platelet reactivity) is not completely under-
stood. It is thought that at least 90% of thrombi in patients
with AF originate in the left atrial appendage [6]. Other
markers of left atrial stasis, like dense spontaneous echo
contrast (DSEC) and low flow velocities (LFV) in the left
atrial appendage [7], are also known to be associated with
thromboembolic complications in patients with AF.
The association of MPV with the different markers of
left atrial stasis (i.e. its role as a marker of increased risk
of cardioembolic stroke) in patients with non-valvular
AF has not yet been addressed.
Aim
To test the accuracy of MPV for predicting markers of
left atrial stasis, detected while using transesophageal
echocardiogram, in patients with non-valvular AF.
Methods
Study population
A single center cross-sectional study was conducted
using the following inclusion and exclusion criteria for
the definition of the assessed population:
Inclusion criteria:
– All patients undergoing echocardiographic
assessment, comprising both transesophageal and
transthoracic echocardiogram, due to symptomatic
AF leading to admission to the Emergency
Department during a 36 months period.
Step-wise exclusion criteria:
– Lack of assessment of MPV in the 12 hours
immediately before the echocardiographic
assessment.
– Valvular AF, defined as rheumatic heart disease,
prosthetic heart valve or previous valve repair and
moderate to severe mitral or aortic valve stenosis or
regurgitation.
– Presence of ongoing infection.
– Diagnosis of acute myocardial infarction during the
index event or in the previous month.
Among a total of 611 subjects, 507 had performed a
complete blood count 12 hours prior to transesophagealechocardiogram and were selected for possible inclusion
the purpose of our investigation. Among these, 28 sub-
jects with valvular AF, 49 with concomitant infection
and 3 with final diagnosis of acute myocardial infarction
were excluded from analysis. Our study population in-
cluded the remaining 427 patients. All subjects provided
their informed consent to undergo the necessary investi-
gations and to allow the usage of their data for research
purposes, preserving their anonymity.
Baseline overall group characterization with demo-
graphic, anthropometric, clinical, laboratory and echocar-
diographic data, alongside with information on medication
was obtained for all patients. Data was retrospectively
retrieved from clinical records (outpatient clinic evalua-
tions, emergency department and hospital ward admis-
sions). This study was conducted with the approval of our
Institution’s Cardiology Department Supervisor and Ethics
Committee.
Echocardiographic data
Transthoracic and transesophageal echocardiogram were
performed using a GE Vivid 7 echocardiograph along-
side with M4S (1.5–4.0 MHz) and 6 T phased array
multiplane transesophageal (2.9–7.0 MHz) probes. All
examinations were performed by two cardiologists with
accreditation in transthoracic and transesophageal echo-
cardiography by the European Society of Cardiology.
Transesophageal echocardiogram was performed with-
out anesthesia or sedation in more than 97% of patients.
Images were later reanalyzed using the GE Health Care
EchoPac Dimension software, PC version 108.1.4. Left
atrium volume was measured using the single-plane area
length method. On transesophageal echocardiogram, the
left atrium and left atrial appendage were imaged in dif-
ferent tomographic planes to detect the presence of
LAAT and DSEC. Spontaneous echo contrast was classi-
fied according to the classification (1 to 4+) proposed by
Fatkin et al. [8]. Grade 3+ or 4+ was defined as DSEC.
Left atrial appendage flow velocities were assessed with a
pulsed Doppler sample placed 1 cm from the entry of
the left atrial appendage into the body of the left atrium.
Emptying and filling velocities were estimated from an
average of five well-defined emptying and filling waves.
Patients with emptying and filling velocity ≤20 cm/s
were classified as having LFV. The presence of at least
one of the previous markers of left atrial stasis (LAAT,
DSEC or LFV) was designated as left atrial abnormality
(LA ABN).
The cardiologists performing the transthoracic and
transesophageal echocardiogram were blinded for the
lab results and clinical information of the patients other
than the fact that they were in AF and there was need
for excluding transesophageal echocardiogram changes
that could contraindicate cardioversion.
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After venous blood was drawn, it was immediately trans-
ferred into our hospital’s laboratory using an automatic
internal tube transference system directly connected
from different parts of the hospital into the laboratory.
On average laboratory measures were performed within
15 minutes of venous blood sampling.
Automated blood cell counting was performed using
the Cell-Dyn Sapphire Hematology Analyzer from Abbot
Diagnostics. Reference range values for complete blood
count data according to local calibration from our hospi-
tal’s laboratory were: hemoglobin – 13.0 to 17.5 g/dL;
leukocytes – 4.0 to 10.0 × 103/μL; platelets – 150 to 400
×103/μL; plaquetocrit – 16.7 to 29.3%; MPV 8.17 to
9.65 fL; platelet distribution width (PDW) 14.7 to 17.4%.
Prediction of transesophageal endpoints
PASW Statistics version 18.0 was used for descriptive
and inferential statistical analysis. Comparisons were
performed according to the presence/absence of all
markers of left atrial stasis. Chi-square was used for
nominal variables and Student’s t-test was used for com-
parison of continuous variables, where appropriate; the
Levene’s test was used in order to check the homogeneity
of variance; equivalent non-parametric tests were used
when Kolmogorov-Smirnov was in favor of absence of
normal distribution. Results with p < 0.05 were regarded
as significant.
Univariate analysis was performed using the chi-square
test. Predictors from univariate analysis were used for
obtaining logistic regression models (using the backward
stepwise method likelihood ratio; probability for stepwise
= 0.10) that could predict all the transesophageal echocar-
diogram endpoints: LAAT, DSEC, LFV and LA ABN.
Continuous variables such as left ventricle ejection
fraction (LVEF), and MPV were converted into ordinal
variables and then used in the logistic regression analysis.
Established cutoff points according to data available in the
literature were: ≥ 55% vs. < 55% [9] and < 40% vs. ≥ 40%
[10] for LVEF; indexed left atrial volume ≥ 60 ml/m2 vs. <
60 ml/m2 [10]; MPV > 9.4 fL vs. ≤ 9.4 fL [5]; troponin I >
0.012 ng/mL vs. non-detectable [11]; body mass index ≥
27.0K g/m2 vs. < 27.0 Kg/m2 [12]. When cut-off values
were not available in the literature, receiver operating char-
acteristic (ROC) curves were traced and using their coordi-
nates we were able to define the optimal cutoff point
(Youden index). The Hosmer-Lemeshow summary statis-
tic was used to assess the goodness-of-fit of the models.
Results
The patients’ baseline clinical, echocardiographic and la-
boratory characterization is shown on Table 1. Average
CHADS2 and CHA2DS2-VASc values were 2.1 ± 1.2 and
3.7 ± 1.7, respectively. Only 147 patients (34.4%) wereunder oral anticoagulation and 73 of these (49.7%) had
an INR ≥ 2.0. In 38.6% (n = 165) of subjects there was no
previously known history of AF.
Mean platelet volume and changes found on
transesophageal echocardiogram
Comparisons of patients with MPV ≤ vs > 9.4 fL are
shown on Table 1. Patients with MPV > 9.4 fL had a
higher prevalence of previous stroke of transient ische-
mic attack (TIA) (OR = 1.706 95%CI 1.004-2.901), a
higher CHADS2 score and were more frequently medi-
cated with angiotensin converting enzyme inhibitors or
angiotensin-II receptor blockers. These patients also
displayed lower platelet count levels, higher rise in
troponin I levels and a more dilated left atrium and left
ventricle.
The following prevalence of markers of left atrial stasis
was found on transesophageal echocardiogram: LAAT in
12.2%, DSEC in 29.7%, LFV in 15.3% and LA ABN in
34.2% (Table 2). These were more frequent in patients
with MPV > 9.4 fL (Tables 2 and 3).
After the analysis of ROC curves concerning the dis-
crimination of LAAT, the following cutoff values for
platelet count and indexed left ventricle diastolic diam-
eter were found: ≥ 240 × 103/uL (sensitivity = 46.8% and
specificity = 67.6%) and ≥ 3.23 mm/m2 (sensitivity =
58.3% and specificity = 75.1%), respectively.
On univariate analysis MPV was a predictor of all
markers of left atrial stasis. Congestive heart failure,
stroke or TIA, AF episode duration, platelet count,
troponin I, iLVdd, iLAV and LVEF were among the other
predictors of LAAT on univariate analysis.
Predictors of DSEC, LFV and LA ABN on univariate
analysis are shown on Table 3.
Incremental value of mean platelet volume to other
predictors of left atrial stasis
On logistic regression, MPV remained an independent
predictor of all markers of left atrial stasis, adding pre-
dictive value to clinical variables (stroke or TIA, con-
gestive heart failure and diabetes mellitus), troponin I
and echocardiographic parameters (indexed left atrial
volume, indexed left ventricle diastolic diameter and
LVEF) that were also included in the predictive models
(Table 4).
MPV was the only variable that could independently
predict the presence of all markers of left atrial stasis.
Discussion
Our data shows that MPV was associated to an in-
creased prevalence of LAAT, DSEC, LVF and LA ABN,
echocardiographic markers that are known to associate
with cardioembolic stroke and an adverse prognosis in pa-
tients with AF. Thus, on logistic regression multivariate
Table 1 Population baseline characteristics and sub-analysis according to mean platelet volume
Overall MPV ≤ 9.4 fL MPV > 9.4 fL P
(n = 427) (n = 245) (n = 182)
Demographics
Age 68.2 ± 10.7 67.5 ± 11.5 69.0 ± 9.3 0.133
♀ 32.1% (137) 31.4% (77) 33.0% (60) 0.736
Body Mass Index (Kg/m2) 28.7 ± 5.2 29.2 ± 4.4 28.1 ± 6.0 0.014
Clinical data
Congestive heart failure 49.4% (211) 45.7% (112) 54.4% (99) 0.076
Hypertension 83.4% (356) 83.3% (204) 83.5% (152) 0.945
Diabetes mellitus 24.6% (105) 24.1% (59) 25.3% (46) 0.777
Stroke or TIA 15.2% (65) 12.2% (30) 19.2% (35) 0.047
Vascular diseasea 49.6% (212) 46.5% (114) 53.8% (98) 0.135
AF episode duration >1 week 77.8% (332) 74.7% (183) 81.9% (149) 0.078
CHADS2 score 2.1 ± 1.2 2.0 ± 1.2 2.3 ± 1.3 0.034
CHA2DS2-VASc score 3.7 ± 1.7 3.5 ± 1.8 3.9 ± 1.7 0.081
Medication
Oral anticoagulants 34.4% (147) 33.9% (83) 35.2% (64) 0.782
Enoxaparin 31.1% (133) 32.2% (79) 29.7% (54) 0.570
Antiplatelet agents 48.9% (209) 48.6% (119) 49.5% (90) 0.857
ACE-i or ARB-II 69.6% (297) 65.7% (161) 74.7% (136) 0.045
Statin 41.2% (176) 39.6% (97) 43.4% (79) 0.428
Laboratory assessment
Haemoglobin (g/dL) 13.8 ± 1.9 13.9 ± 1.9 13.6 ± 1.8 0.089
Leukocytes (103/uL) 7.5 ± 3.1 7.4 ± 2.8 7.8 ± 3.6 0.247
Platelets (103/uL) 222.6 ± 86.2 240.6 ± 95.2 198.4 ± 65.1 <0.001
Plaquetocrit (%) 20.5 ± 7.2 20.8 ± 7.9 20.2 ± 6.2 0.774
MPV (fL) 9.3 ± 1.1
PDW (%) 16.2 ± 1.3 16.1 ± 1.4 16.3 ± 1.2 0.151
INR 1.4 ± 0.7 1.4 ± 0.7 1.4 ± 0.7 0.583
INR≥ 2.0 17.1% (73) 16.3% (40) 18.1% (33) 0.624
aPTT time (s) 34.1 ± 7.7 33.0 ± 6.0 35.6 ± 9.5 0.078
Creatinine (umol/L) 111.7 ± 93.9 111.4 ± 107.8 112.1 ± 71.4 0.329
Estimated GFR – MDRD 71.1 ± 27.5 72.4 ± 26.8 69.3 ± 28.5 0.262
CRP (mg/L) 1.7 ± 3.5 1.5 ± 2.7 2.1 ± 4.3 0.213
Troponin I (ng/mL) 0.03 ± 0.07 0.03 ± 0.04 0.04 ± 0.10 0.032
Transthoracic echocardiogram data
iLAV (ml/m2) 60.4 ± 24.5 56.7 ± 21.9 64.7 ± 26.6 0.006
iLVdd (mm/m2) 29.6 ± 5.6 28.8 ± 5.5 30.5 ± 5.6 0.010
LVEF < 55% 24.8% (106) 24.5% (60) 25.3% (46) 0.853
Legend: MPV Mean platelet volume, TIA Transient ischemic attack, AF Atrial fibrillation, ACE-i Angiotensin converting enzyme inhibitor, ARB-II Angiotensin II
receptor blocker, PDW Platelet distribution width, INR International normalized ratio, CRP, C reactive protein, GFR Glomerular filtration rate, MDRD Modified diet in
renal disease formula, LV Left ventricle, LAAT Left atrial appendage thrombi, DSEC Dense spontaneous echo contrast, LFV flow velocities Lowin the left atrial
appendage, LA ABN Left atrial abnormality, aPTT Activated partial thromboplastin time, iLAV Indexed left atrial volume, iLVdd Indexed left ventricle diastolic
diameter, LVEF Left ventricle ejection fraction.
a vascular disease is defined as having at least one of the following: myocardial infarction, peripheral artery disease and complex aortic plaque.
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clinical parameters from the CHADS2 score (congestive
heart failure, stroke or TIA and diabetes mellitus), echo-
cardiographic parameters (indexed left atrial volume,
indexed left ventricle diastolic diameter and LVEF) andother biomarkers (troponin I), as far as prediction of all
transesophageal echocardiogram markers of left atrial sta-
sis are concerned.
These results suggest that the recently described in-
creased prevalence of stroke in patients with AF and
Table 2 Presence of left atrial stasis on transesophageal
echocardiogram and sub-analysis according to mean
platelet volume
Overall MPV ≤ 9.4 fL MPV > 9.4 fL P
(n = 427) (n = 245) (n = 182)
LAAT 12.2% (52) 9.0% (22) 16.5% (30) 0.019
DSEC 29.7% (127) 23.7% (58) 37.9% (69) 0.001
LFV 15.3% (54/354)a 9.1% (19/208) 24.0% (35/146) <0.001
LA ABN 34.2% (146) 27.3% (67) 43.4% (79) 0.001
Legend: MPV Mean platelet volume, LAAT Left atrial appendage thrombi, DSEC
Dense spontaneous echo contrast, LFV Low flow velocities in the left atrial
appendage, LA ABN Left atrial abnormality.
a only 354 subjects had assessment of left atrial appendage flow velocities due
to technical or procedural reasons (see Discussion).
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which reinforces the importance of our findings in the
management of patients with AF:
First, in patients undergoing procedures like cardiover-
sion or AF ablation, a transesophageal echocardiogram
(a semi-invasive and highly uncomfortable exam for
most patients) is frequently needed in order to rule out
the presence of LAAT. By proving the association of
MPV with this type of marker, we may contribute to the
future development of probabilistic risk scores, combin-
ing several variables, that may allow the selection of pa-
tients who can be spared this examination (since they
are very low risk), or identify those that are very high
risk, and therefore must necessarily perform it to pre-
vent thromboembolic complications related to the
procedure.
Second, a possible explanation for the association of
MPV with stroke could be the increased platelet reactiv-
ity leading to peripheral thrombi formation. By showing
that this may, in fact, be due to cardioembolism, ad-
equate therapeutic interventions may be pursued or de-
veloped for targeting these alterations in patients with
AF who test positive for this marker.
Third, novel biomarkers are now being tested in pa-
tients with AF in order to improve thromboembolic risk
stratification [13]. By demonstrating that MPV possibly
associates with stroke due to a cardioembolic mechan-
ism, we provide rationale for its future prospective as-
sessment both separately and as part of risk scores
designed for the AF population.
Larger platelets are thought to be younger, more react-
ive and more thrombogenic [14,15]. MPV seems to re-
flect both proinflammatory and prothrombotic states
[16]. An association of increased MPV with risk factors
like diabetes mellitus, hypertension and smoking has
been known for some time [17]. An elevated MPV has
been found in paroxysmal AF patients when compared
to subjects in sinus rhythm [18]. In our study, patients
with MPV > 9.4 fL displayed a trend for a higherprevalence of AF episodes lasting for more than one
week, which is concordant with these results.
The only investigation assessing the relation between
left atrial stasis markers (focusing only on LAAT) and
MPV provided negative results towards an association
[19]. Still, some points need to be clarified regarding that
study: first, it included 18.0% (n = 37) patients with se-
vere mitral stenosis (the number of patients with lower
levels of mitral stenosis is not clarified in the manu-
script), which may account for the highly unusual ele-
vated prevalence of LAAT (46.8%; n = 96) that was
described. Second, the average MPV value was approxi-
mately 10.6 fL. That was well over the one we found in
our sample (9.3 ± 1.1 fL). Therefore, in our perspective
these two studies cannot be appropriately compared.
Based on investigations concerning the composition of
spontaneous echocardiographic contrast (thought to be
composed of aggregated activated platelets and leucocytes
[20]) we are lead into thinking that the association of
mean platelet volume with left atrial stasis is not merely
due to chance.
Thromboembolic risk stratification of patients with AF
is currently based on clinical schemes: the CHADS2 [21]
and CHA2DS2-VASc score [22]. Still, these classifications
have not proved to be as effective in the setting of evalu-
ating patients before AF ablation or cardioversion [23].
In our population, some of the parameters that are part
of these classifications, like age, female gender, hyperten-
sion and vascular disease, were not independent predic-
tors of left atrial stasis. The same applies to body mass
index [12] that displayed no predictive value in our
sample.
Troponin I has already been associated both with
thromboembolism [13] and with markers of left atrial
stasis [11] in AF patients. Concerning indexed left atrial
volume, it has been shown to be a predictor of LAAT
formation in AF patients [24], but it is still currently
lacking a definite proof of its role in thromboembolic
risk stratification of patients with AF.
As far as echocardiographic assessment of the left ven-
tricle is concerned, evidence has been more robustly in
favor of an association between both LVEF and LAAT
[23,25] and between LVEF and systemic embolism [10].
Conversely, evidence is very scarce concerning the role
of indexed left ventricle diastolic diameter for the pre-
diction of any thromboembolic endpoint.
To best of our knowledge this is the first report of an
association between MPV with markers of left atrial sta-
sis. In face of these results, we may hypothesize that
mean platelet volume may be used in the future for
assessing patients that are candidates to procedures like
catheter ablation or cardioversion of atrial fibrillation.
Moreover, these data support the need of its prospective
assessment for risk stratification of AF. Due to its wide
Table 3 Univariate analysis of parameters eventually associated transesophageal echocardiogram endpoints
Variable LAAT DSEC LFV LA ABN
OR P OR P OR P OR P
CI95% CI95% CI95% CI95%


























0.85-2.97 1.11-2.80 0.48-1.87 1.16-2.87








0.78-3.02 0.77-1.93 0.51-1.83 0.89-2.16








0.47-1.75 0.36-0.95 0.32-1.27 0.45-1.10


























0.62-2.10 0.84-2.02 0.93-3.03 0.88-2.04








0.45-1.60 0.74-1.86 0.40-1.37 0.68-1.64








>1 week 1.62-17.44 1.19-3.67 0.97-5.16 1.34-3.94








1.11-3.60 1.29-3.00 1.71-5.75 1.36-3.06








0.99-3.39 0.90-2.15 0.57-2.00 0.91-2.13








1.39-17.41 1.75-6.42 1.40-9.15 1.85-6.48








2.01-8.49 1.07-3.06 2.36-9.22 1.43-4.01








2.10-9.85 2.57-7.40 3.13-13.82 2.76-7.73








1.53-5.08 2.62-6.64 0.83-3.12 2.38-5.95








1.57-5.74 3.34-10.02 0.79-3.71 3.18-9.68
Legend: LAAT Left atrial appendage thrombi, DSEC Dense spontaneous echo contrast, LFV Low flow velocities in the left atrial appendage, LA ABN Left atrial
abnormality, OR Odds ratio, CI Confidence interval, TIA Transient ischemic attack, BMI Body mass index, AF Atrial fibrillation, MPV Mean platelet volume, iLAV
Indexed left atrial volume, iLVdd Indexed left ventricle diastolic diameter, LVEF Left ventricle ejection fraction.
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tential candidate for this setting.
Study limitations
A low prevalence of patients undergoing oral anti-
coagulation was found in our sample. Still, we reinforce
that 165 patients (38.6%) had no previous diagnosis of AF.
If we consider only patients with previously known AF the
prevalence of patients undergoing oral anticoagulationrises steeply to 56.1% (147 out of 262). Therefore, our re-
sults can be applied to patients presenting to the emer-
gency department due to symptomatic AF, but probably
not to different subsets of patients, like those undergoing
percutaneous AF ablation, who have an expected very high
prevalence of oral anticoagulation.
Patients over age of 75 displayed a lower prevalence of
DSEC on univariate analysis, that was not confirmed
after correction for other variables. This may be due to a
Table 4 Binary logistic regression multivariate analysis models for predicting the presence of markers of left
atrial stasis








0.005 χ2 = 9.093
1.650-17.317
MPV > 9.4 fL
3.899 1.226
3.408
0.048 df = 6
1.009-11.512










0.006 χ2 = 1.391
1.273-4.256
MPV > 9.4 fL
4.723 0.642
1.900







Constant 6.084 −0.654 0.520 0.014
LFV
MPV > 9.4 fL
4.629 1.257
3.515












Constant 0.444 −0.349 0.705 0.505
LA ABN




iLAV≥ 60 ml/m2 11.504 1.493 4.451
0.001
1.878-10.549




DM 4.952 1.065 2.902
0.026
1.136-7.418




Constant 17.359 −3.249 0.039 <0.001
Legend: LAAT Left atrial appendage thrombi, DSEC Dense spontaneous echo contrast, LFV Low flow velocities in the left atrial appendage, LA ABN Left atrial
abnormality, CI Confidence interval, TIA Transient ischemic attack, LVEF Left ventricle ejection fraction, MPV Mean platelet volume, iLAV Indexed left atrial volume,
iLVdd indexed left ventricle diastolic diameter.
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very symptomatic and have a preserved biological age
for the transesophageal echocardiogram and subsequent
cardioversion strategy. As they usually have less risk fac-
tors and less severe disease than frail elderly who are dir-
ectly referred to rate control strategy, this leads to the
observed trend for lower prevalence of some markers of
left atrial stasis in the transesophageal echocardiogram
plus rhythm control strategy.
73 patients (17.1%) had no evaluation of left atrial ap-
pendage flow velocities. This was due to technical reasons(echocardiographic data being classified as unsuitable for
the accurate assessment of flow velocities) or lack of probe
tolerance by the patients (sedation was used in less than
3% of patients). In these subjects, transesophageal echo-
cardiogram was performed without measurement of left
atrial appendage flow velocities if the presence of LAAT
and DSEC could be excluded right away.
Conclusions
Our results, using left atrial stasis markers, suggest that
mean platelet volume are associated with the presence
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findings support the likely role of a cardioembolic mech-
anism in the association between mean platelet volume
and stroke in patients with non-valvular atrial fibrillation,
reinforcing the possible usefulness of anticoagulation in
this patient subset.
Further prospective investigations (derivation and valid-
ation studies) will be necessary to confirm the plausibility
and role of mean platelet volume as a part of risk models
aiming to discriminate the presence of left atrial append-
age thrombus in atrial fibrillation patients undergoing pro-
cedures like percutaneous ablation or cardioversion.
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